FDA

UNIVERSAL data supports Laurus Labs US FDA submission for approval of novel protease inhibitor

2024

Laurus Labs has submitted an application to the US Food and Drug Administration (FDA) for the tentative approval of paediatric Darunavir/ritonavir (pDRV/r (120/20 mg)). UNIVERSAL is the first product development project from the World Health Organisation’s (WHO) GAP-F project which was established to promote the development of safer,

Read More